MarkA.GrahamMD

PubMed

• 69 citations
  Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2
  Richard A. Ward, Nicola Colclough, Mairi Challinor, Judit E. Debreczeni, Kay Eckersley, Gary Fairley, Lyman Feron, Vikki Flemington, Mark A. Graham, Ryan Greenwood, Ph...> ;Journal of Medicinal Chemistry. 2015 May 28
• 7 citations
  Synthesis of functionalized cyanopyrazoles via magnesium bases.
  Allan Dishington, J. Lyman Feron, Kathryn Gill, Mark A. Graham, Ian A. Hollingsworth, Jennifer H. Pink, Andrew D. Roberts, Iain Simpson, Matthew R. Tatton> ;Organic Letters. 2014 Nov 13
• 3 citations
  Novel and versatile synthesis of disubstituted 1,2-dihydro-1,2,4-triazol-3-ones.
  Mark A. Graham, Paul A. Bethel, Jonathan Burgess, Gary Fairley, Steve C. Glossop, Ryan Greenwood, Clifford David Jones, Scott Lovell, Steve Swallow> ;Organic Letters. 2013 Nov 18
• 20 citations
  Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.
  M. Raymond V. Finlay, David Buttar, Susan E. Critchlow, Allan Dishington, Shaun M. Fillery, Eric Fisher, Steve C. Glossop, Mark A. Graham, Trevor Johnson, Gillian M. L...> ;Bioorganic & Medicinal Chemistry Letters. 2012 Jun 15
• 41 citations
  The importance of the N-H bond in Ru/TsDPEN complexes for asymmetric transfer hydrogenation of ketones and imines.
  Rina Soni, Fung Kei Cheung, Guy C. Clarkson, Jose E. D. Martins, Mark A. Graham, Martin Wills> ;Organic & Biomolecular Chemistry. 2011 Apr 12
• 23 citations
  Kinetic and structural studies on 'tethered' Ru(II) arene ketone reduction catalysts.
  Fung Kei Cheung, Adam J. Clarke, Guy J. Clarkson, David J. Fox, Mark A. Graham, Changxue Lin, Adriana Lorente Crivillé, Martin Wills> ;Dalton Transactions. 2010 Jan 19
• 32 citations
  The Discovery of Azd5597, a Potent Imidazole Pyrimidine Amide Cdk Inhibitor Suitable for Intravenous Dosing.
  Clifford David Jones, David M. Andrews, Barker Andrew John, Kevin Blades, Paula Daunt, S J East, Catherine Geh, Mark A. Graham, Keith M. Johnson, Sarah A. Loddick, Hea...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Dec 15
• 21 citations
  Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode
  M. Raymond V. Finlay, David G. Acton, David M. Andrews, Barker Andrew John, Michael Dennis, Eric Fisher, Mark A. Graham, Clive Green, David William AstraZeneca R D Ald...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Aug 1
• 4 citations
  Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.
  David M. Andrews, Keith Hopkinson Macclesfield Gibson, Mark A. Graham, Zbigniew Stanley Matusiak, Craig A. Roberts, Stokes Elaine Sophie Elizabeth, Madeleine C. Brady,...> ;Bioorganic & Medicinal Chemistry Letters. 2008 Apr 15
• 52 citations
  An Investigation into the Tether Length and Substitution Pattern of Arene-Substituted Complexes for Asymmetric Transfer Hydrogenation of Ketones
  Fung Kei Cheung, Changxue Lin, Franco Minissi, Adriana Lorente Crivillé, Mark A. Graham, David J. Fox, Martin Wills> ;Organic Letters. 2007 Sep 27
• 3 citations
  Studies on the Lewis acid mediated cleavage of α-aminoacetals: synthesis of novel 1,2-aminoethers, and evidence for α-alkoxy aziridinium ion intermediates
  Mark A. Graham, Alan H. Wadsworth, Abdul Zahid, Christopher M. Rayner> ;Organic & Biomolecular Chemistry. 2003 Feb 27
• Phase I pharmacokinetic study of the novel antitumor agent SR233377.
  LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH> ;Clin. Cancer Res.. 2000-08-01
• Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurem...
  Aboagye EO, Maxwell RJ, Kelson AB, Tracy M, Lewis AD, Graham MA, Horsman MR, Griffiths JR, Workman P> ;Cancer Res.. 1997-08-01
• Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.
  Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, Kaye SB> ;Clin. Cancer Res.. 1997-01-01
• Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
  McLeod HL, Murray LS, Wanders J, Setanoians A, Graham MA, Pavlidis N, Heinrich B, ten Bokkel Huinink WW, Wagener DJ, Aamdal S, Verweij J> ;Br. J. Cancer. 1996-12-01
• In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
  McLeod, H. L., Brunton, V. G., Eckardt, N., Lear, M. J., Robins, D. J., Workman, P., Graham, M. A.> ;Br J Cancer. 1996 Dec
• The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
  Aboagye EO, Lewis AD, Graham MA, Tracy M, Kelson AB, Ryan KJ, Workman P> ;Anticancer Drug Des.. 1996-04-01
• Development and validation of a solid-phase extraction and high-performance liquid chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe (SR-455...
  Aboagye EO, Graham MA, Lewis AD, Workman P, Kelson AB, Tracy M> ;J. Chromatogr. B, Biomed. Appl.. 1995-10-06
• Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major...
  Robin H, Senan S, Workman P, Graham MA> ;Cancer Chemother. Pharmacol.. 1995-01-01
• Pharmacokinetics and cancer chemotherapy.
  Workman, P., Graham, M. A.> ;Eur J Cancer. 1994
• Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-...
  Riley RJ, Hemingway SA, Graham MA, Workman P> ;Biochem. Pharmacol.. 1993-03-09
• Pharmacokinetics and early clinical studies of selected new drugs.
  Kaye SB, Workman P, Graham MA, Cassidy J, Jodrell D> ;Cancer Surv.. 1993-01-01
• Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues.
  Luqmani YA, Graham M, Coombes RC> ;Br. J. Cancer. 1992-08-01
• The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.
  Graham MA, Workman P> ;Ann. Oncol.. 1992-05-01
• Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
  Graham MA, Newell DR, Foster BJ, Gumbrell LA, Jenns KE, Calvert AH> ;Cancer Res.. 1992-02-01
• Join now to see all